# US 2012/0252842 A1 · Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252842 A1
- Document ID: US20120252842A1
- Status: Published application
- Kind: A1
- Application number: 13/492,038
- Filed: 2012-06-08
- Published: 2012-10-04
- Earliest claimed: 2006-12-11
- Assignees: Reviva Pharmaceuticals, Inc.
- Inventors: Laxminarayan BHAT; Prabhu Prasad MOHAPATRA
- Web page: https://patentgrep.com/patent/US20120252842A1

## CPC

- C07D 211/22: by oxygen atoms
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides novel indanone derivatives which can be advantageously used for treating and/or preventing of a medical condition for which inhibition of a cholinesterase is desired.

## Claims

### Claim 1

An indanone derivative of structural Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
X is O, S, or NH;
SP is -alkylaryl, -alkylaryl-O-alkylene-, -alkylaryl-C(O)O-alkylene-, -alkylaryl-CONH-alkylene-, or -alkylaryl-OCH2C(O)NH-alkylene-;
B is —(CH2)n—, —(CH2)nC(O)—, —(CH2)nC(O)O—, —(CH2)nOC(O)—, —(CH2)nS(O)(O)—, —(CH2)nNHC(O)—, O, S, —C(O), —C(O)O, or —S(O)(O), wherein n is an integer between 1 and 5;
R1 is H;
R2 and R3 are independently H, alkoxy, or halogen;
R4 and R5 are independently H or alkyl;
R6 is arylalkyl or substituted arylalkyl; and
R7 is H or alkyl.

### Claim 2 (depends on 1)

The indanone derivative according to claim 1, wherein SP is -alkylaryl.

### Claim 3 (depends on 1)

The indanone derivative according to claim 1, wherein SP is -alkylaryl-O-alkylene.

### Claim 4 (depends on 1)

The indanone derivative according to claim 1, wherein SP is -alkylaryl-C(O)O-alkylene.

### Claim 5 (depends on 1)

The indanone derivative according to claim 1, wherein SP is -alkylaryl-CONH-alkylene-.

### Claim 6 (depends on 1)

The indanone derivative according to claim 1, wherein SP is -alkylaryl-OCH2C(O)NH-alkylene-.

### Claim 7 (depends on 1)

The indanone derivative according to claim 1, wherein B is —(CH2)n—.

### Claim 8 (depends on 7)

The indanone derivative according to claim 7, wherein B is —(CH2)—.

### Claim 9 (depends on 1)

An indanone derivative of structural Formula (IV), according to claim 1,

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is for oral, mucosal, rectal, parenteral, transdermal, or subcutaneous administration.

### Claim 12 (depends on 1)

A method for treating Alzheimer's disease, comprising the step of administering to a patient in need thereof an indanone derivative according to claim 1.

### Claim 13 (depends on 1)

A method for treating myasthenia gravis, comprising the step of administering to a patient in need thereof an indanone derivative according to claim 1.

### Claim 14 (depends on 1)

A method for treating Huntington's disease, comprising the step of administering to a patient in need thereof an indanone derivative according to claim 1.

### Claim 15 (depends on 1)

A method for treating glaucoma, comprising the step of administering to a patient in need thereof an indanone derivative according to claim 1.
